Awards Nomination 20+ Million Readerbase
Indexed In
  • Academic Journals Database
  • Open J Gate
  • Genamics JournalSeek
  • JournalTOCs
  • China National Knowledge Infrastructure (CNKI)
  • Scimago
  • Ulrich's Periodicals Directory
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • Publons
  • MIAR
  • University Grants Commission
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
Share This Page

Vaccine Adjuvants and Delivery Technologies

     A Vaccine adjuvant is an ingredient of a vaccine that helps create a stronger immune response in the patient’s body.  In other words, adjuvants help vaccines work better. Some vaccines made from weakened or dead germs contain naturally occurring adjuvants and help the body produce a strong protective immune response. However, most vaccines developed today include just small components of germs, such as their proteins, rather than the entire virus or bacteria. These vaccines often must be made with adjuvants to ensure the body produces an immune response strong enough to protect the patient from the germ he or she is being vaccinated against. Aluminum gels or aluminum salts are vaccine ingredients that have been used in vaccines since the 1930s.  Small amounts of aluminum are added to help the body build stronger immunity against the germ in the vaccine. Aluminum is one of the most common metals found in nature and is present in air, food, and water. The amount of aluminum present in vaccines is low and is regulated by the U.S. Food and Drug Administration (FDA).

     As a part of this special issue researchers and scholars are invited to submit manuscripts on all aspect of vaccines research but not limited to the topics such as New vaccine technology including adjuvants and delivery systems, Next-Generation Adjuvants, Advances in DNA Vaccines, TLRS and Combination Adjuvants, Addressing Unmet Vaccine Needs, DNA delivery technologies, Needle-free vaccine delivery, Nanopatch Technologies, Adjuvants and Delivery systems for prophylactic and therapeutic vaccines,  etc.
 
     The Journal follows a stringent double blind peer review process for all submitted manuscripts. We welcome manuscripts for the special issue till “December 25th, 2020”. The submitted manuscripts would be published by “December 22th, 2020”. As the submission for the special issue would be limited in number & would be processed on a First come First Serve basis.

You may submit your paper by or online at  https://www.longdom.org/submissions/vaccines-vaccination.html or e-mail at  manuscripts@walshmedicalmedia.com

 



This Special issue is being edited by

Wang Ji

Harvard Medical School
USA